Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.
Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R.
Janku F, et al. Among authors: kee bk.
Oncotarget. 2015 May 20;6(14):12809-21. doi: 10.18632/oncotarget.3373.
Oncotarget. 2015.
PMID: 25980577
Free PMC article.